Filing Flows › Bioventus (BVS) › Capital expenditures
Bioventus (BVS) capital expenditures by quarter
Bioventus' capital expenditures were $334K in Q3 2026 (third quarter 2026), -65% from Q2 2026. Over the last 6 quarters it ranged from $334K (Q3 2026) to $960K (Q2 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $334K | -65% | -29% |
| Q2 2026 | $960K | +67% | +41% |
| Q1 2026 | $574K | -1% | — |
| Q4 2025 | $580K | +23% | — |
| Q3 2025 | $473K | -31% | — |
| Q2 2025 | $683K | — | — |
Q3 2026 at a glance
Bioventus, Q3 2026: revenue $142M (+3% year over year), operating margin 6.8%, net earnings $6.0M, operating cash flow $20.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Bioventus' capital expenditures?
Bioventus' capital expenditures were $334K in Q3 2026 (third quarter 2026), -65% from Q2 2026.
How has Bioventus' capital expenditures changed?
Over the last 6 quarters it ranged from $334K (Q3 2026) to $960K (Q2 2026).